The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20418194.
- Also identified by DOI 10.1016/j.pcd.2010.03.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effective identification and management of type 2 diabetes (T2D) in primary care is a healthcare priority. New antidiabetic agents, including glucagon-like peptide (GLP)-1 receptor agonists, may help overcome drawbacks with current treatments. These new agents have been reviewed in the updated National Institute for Health and Clinical Excellence (NICE) guidelines for the treatment of T2D. Liraglutide, a GLP-1 receptor agonist, was licensed for use in patients with T2D after the development of the NICE guidelines. Data from Phase III trials evaluating liraglutide are presented here in the context of the role of GLP-1 receptor agonists in NICE guidelines.
Medical subject headings
- Clinical Trials, Phase III as Topic
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptide 1
- Hypoglycemic Agents
- Practice Guidelines as Topic
- Randomized Controlled Trials as Topic